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A frameshift mutation 138delT generates an open
reading frame in the pseudogene, cytochrome P4502D7
(CYP2D7), and an alternate spliced functional transcript
of CYP2D7 containing partial inclusion of intron 6 was
identified in human brain but not in liver or kidney
from the same individual. mRNA and protein of the
brain variant CYP2D7 were detected in 6 of 12 human
autopsy brains. Genotyping revealed the presence of the
frameshift mutation 138delT only in those human sub-
jects who expressed the brain variant CYP2D7. Genomic
DNA analysis in normal volunteers revealed the pres-
ence of functional CYP2D7 in 4 of 8 individuals. In liver,
the major organ involved in drug metabolism, a minor
metabolic pathway mediated by CYP2D6 metabolizes
codeine (pro-drug) to morphine (active drug), whereas
norcodeine is the major metabolite. In contrast, when
expressed in Neuro2a cells, brain variant CYP2D7 me-
tabolized codeine to morphine with greater efficiency
compared with the corresponding activity in cells ex-
pressing CYP2D6. Morphine binds to -opioid receptors
in certain regions of the central nervous system, such as
periaqueductal gray, and produces pain relief. The
brain variant CYP2D7 and -opioid receptor colocalize
in neurons of the periaqueductal gray area in human
brain, indicating that metabolism of codeine to mor-
phine could occur at the site of opioid action. Histio-
specific isoforms of P450 generated by alternate splic-
ing, which mediate selective metabolism of pro-drugs
within tissues, particularly the brain, to generate active
drugs may play an important role in drug action and
provide newer insights into the genetics of metabolism.
Cytochrome P450 (EC 1.14.14.1; P450)1 and associated mo-
nooxygenases, a family of heme proteins, are the principal class
of drug-metabolizing enzymes. A supergene family encodes
them, and the member proteins exist as multiple forms having
distinct yet overlapping substrate specificities. Multiple forms
of P450, which are selectively induced or inhibited by a variety
of drugs, are known to exist in liver, the major organ involved
in P450-mediated metabolism (1). However, the potential to
generate active metabolite(s) at the site of action has generated
interest in extrahepatic P450. This has prompted extensive
investigations into the xenobiotic metabolizing capability of
extrahepatic organs, such as lung, kidney, skin, and nasal
epithelium, and the far reaching consequences of such metab-
olism, in situ, within specific cells in target organs have been
recognized in laboratory animals (2) and humans (3). The pref-
erential localization of drug-metabolizing enzymes within spe-
cific cell types in these organs renders such cells significantly
capable of metabolizing drugs (4). Thus, even minor metabolic
pathways of xenobiotic metabolism can produce major effects if
they take place at the site of action. These observations have
prompted investigation into P450-associated monooxygenases
in brain with an effort to determine the capability of the brain
to metabolize psychoactive drugs (5, 6). P450-mediated metab-
olism of psychoactive drugs directly in the brain can lead to
local pharmacological modulation at the site of action and
result in variable drug response.
The interindividual variability in hepatic metabolism of
drugs caused by genetic polymorphism exhibited by some forms
of P450 such as P4502D6 are reflected in the plasma levels of
administered drugs. But plasma drug levels often show poor
correlation with therapeutic effect (7), suggesting that metab-
olism within the brain could influence the therapeutic outcome
regardless of hepatic clearance and plasma drug levels. A mod-
erate difference in the pharmacokinetics of psychoactive drugs
often leads to dramatic pharmacodynamic effects, again sug-
gesting that metabolism in situ within the brain could play a
significant role (8).
Over the past decade studies from our laboratory and others
have demonstrated the presence of a competent microsomal
P450 system in the rodent (2, 9, 10) and human (3, 11) brain
and its ability to metabolize a variety of xenobiotics. The ap-
pearance of multiple forms of P450 in brain and their selective
inducibility by a variety of drugs and xenobiotics have also
been identified (9, 12–14). CYP2D is one of the major forms of
P450 present in both rat (15) and human brain (16). Significant
differences are seen in the regulation and function of the iso-
forms of brain P450 compared with the hepatic forms (17–19).
For example, drugs such as alprazolam are metabolized differ-
ently in liver and brain wherein a relatively larger amount of
the active metabolite is generated in the brain compared with
liver (19). These observations have indicated the possible ex-
istence of unique P450 isoforms in brain that are different from
* This work was supported by National Institutes of Health Grant
MH55494. The costs of publication of this article were defrayed in part
by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted
to the GenBankTM/EBI Data Bank with accession number(s) AY220845.
 To whom correspondence should be addressed: Molecular and Cel-
lular Neuroscience, National Brain Research Centre, Nainwal Mode,
Manesar, Haryana 122050, India. E-mail: vijir@nbrc.ac.in.
1 The individual human cytochrome P450 gene is represented as CYP
followed by an Arabic number denoting family and an alphabetical
letter designating subfamily (CYP2D). An Arabic number is used to
represent genes within a subfamily (e.g. CYP2D6). Cytochrome P450
protein is represented with a prefix P450 (P4502D6) in a similar
manner.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 279, No. 26, Issue of June 25, pp. 27383–27389, 2004
Printed in U.S.A.
This paper is available on line at http://www.jbc.org 27383
 by guest, on M
ay 23, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
the well characterized hepatic P450s. We report here the pres-
ence of a unique form of CYP2D7 that is generated by alternate
splicing in human brain but not in liver or kidney.
EXPERIMENTAL PROCEDURES
Human brain was obtained from Human Brain Tissue Repository,
NIMHANS, India. The tissue was collected at autopsy from male and
female traffic accident victims with no known neurological or psychiat-
ric disorders. The average age of the individuals was 35.4 years (3–70
years), and postmortem delay between death and autopsy was 7.3 
3.7 h. A region representing exon 6–9 of CYP2D6 (333 bp) was amplified
by RT2-PCR with forward and reverse primers 5-TGATGAGAACCT-
GCGCATAG-3 and 3-ACCGATGACAGGTTGGTGAT-5, respectively,
using human cortex mRNA and used for screening a human cortex
cDNA library constructed in our laboratory using Lambda ZAPII li-
brary construction kit (Stratagene, La Jolla). Three positive clones of
1.2, 1.5, and 1.8 kb were isolated and sequenced. The 1.8-kb clone
referred to as brain variant CYP2D7 (GenBank accession number
AY220845) containing an open reading frame was used for further
investigations.
Expression of Brain Variant CYP2D7—In vitro translation was car-
ried out using a TNT T3-coupled reticulocyte system (Promega,
Madison, WI) and brain variant CYP2D7 cDNA. The translated prod-
ucts were examined by immunoblot using antibody to CYP2D6 (Gen-
test, San Jose, CA) (19). Luciferase cDNA provided by the manufacturer
was used as a positive control. The cDNA of brain variant CYP2D7 was
subcloned into pcDNA3.1 (/), sequence verified, and transfected into
Neuro2a cells using FuGENE 6 (Roche Applied Science). Positive clones
were selected using neomycin. Cells were harvested, and a membrane
preparation containing both mitochondria and microsomes was pre-
pared as described earlier (16). Neuro2a cells were also grown in cham-
ber slides and processed for immunohistochemistry using antibody to
CYP2D6. Immunostaining was visualized by incubation with biotiny-
lated secondary antibody followed by streptavidin-fluorescein. cDNA to
brain variant CYP2D7 ligated in the reverse orientation was used as a
control in transfection experiments.
RT-PCR and Genomic DNA Amplification—RT-PCR was carried out
using cDNA synthesized from total RNA of 12 autopsy human brain
samples. PCR was performed using the forward and reverse primers,
5-GGCCAAGGGGAACCCTGAGA-3 and 5-GGTCATACCCAGGGG-
GACGA-3, respectively. Two PCR products of 340 bp (809–1148 bp of
brain variant CYP2D7) and 282 bp (843–1125 bp of CYP2D6, GenBank
accession number M20403) were amplified.
Genomic DNA was extracted from human brain cortex or blood and
PCR amplified using forward and reverse primers, 5-CTTCCTGCTC-
CTGGTGGA-3 and 5-CACCCCCTTCATCCTCGA-3, respectively,
spanning 506 bp of the partial sequences of exon 1 and intron 1 of the
genomic sequence of CYP2D7 (45–551 bp relative to the ATG start
codon of the genomic sequence of CYP2D7; GenBank accession number
NG_002362). PCR products were examined by electrophoresis and
sequenced.
Localization of Brain Variant CYP2D7 by in Situ Hybridization—
The 340-bp RT-PCR product was ligated into pCRII vector, and digoxi-
genin-labeled sense and antisense riboprobes were generated. In situ
hybridization was performed using paraffin-embedded sections of
brain, liver, and kidney from the same individual. Digoxigenin-labeled
riboprobes were also generated from the cDNA to CYP2D6 (GenBank
accession number M20403). Human brain cortex, liver, and kidney
obtained at autopsy from the same individual were fixed in buffered
paraformaldehyde (4%, w/v) prior to paraffin embedding. Serial sec-
tions (8–10 m thick) were cut under RNase-free conditions. Sections
were dewaxed, hydrated in graded ethanol, acetylated, and treated with
proteinase K. The sections were then rinsed in phosphate-buffered
saline and dehydrated using graded ethanol. Sections were hybridized
overnight with the digoxigenin-labeled riboprobes. After hybridization
sections were washed, incubated with blocking reagent (0.5%, w/v,
PerkinElmer Life Sciences) followed by antibody to digoxigenin conju-
gated to horseradish peroxidase. After washing, sections were incu-
bated with biotinylated tyramine followed by streptavidin-fluorescein.
Finally the sections were washed, dried, and mounted prior to exami-
nation under fluorescence microscope.
Preparation of Antiserum to Brain Variant CYP2D7—An antigen
derived from the 19-amino acid peptide (GRRVSPGCSPIVGTHVCPV)
representing 57 bp of intron 6 of brain variant CYP2D7 was conjugated
to bovine serum albumin at the N-terminal end and used to generate
antiserum to brain variant CYP2D7 in rabbits. The antiserum was
verified for lack of cross-reactivity with P4502D6 and used for
immunoblotting.
Immunoblotting with Membrane Preparations from Human Brain—
Brain membrane preparations containing microsomal and mitochon-
drial protein (200 g each) isolated from the cortex obtained at autopsy
from the 12 human subjects were analyzed by SDS-PAGE (19). The
blots were incubated sequentially with antiserum to brain variant
CYP2D7 (1:200 dilution) overnight at 4 °C and anti-rabbit IgG conju-
gated to alkaline phosphatase (1:1,000 dilution) for 2 h at room tem-
perature. Color was developed using chromogenic substrates for the
alkaline phosphatase.
Assay of P450 and Metabolism of Codeine—Brain variant CYP2D7
was expressed in Neuro2a cells as described above, and the membrane
preparation containing both mitochondria and microsomes was iso-
lated. Total cytochrome P450 content in membrane preparation was
measured from a carbon monoxide reduced minus oxidized difference
spectrum (9). Membrane preparation (150 g of protein) was incubated
at 37 °C in Tris-HCl (50 mM, pH 7.4) containing 20 mM MgCl2, 1 unit of
purified liver NADPH-cytochrome P450 reductase (20), and 0.01–1 mM
codeine. The reaction was initiated by the addition of 1 mM NADPH and
stopped after 30 min by addition of acetonitrile (10% of total volume).
The samples were centrifuged, filtered, and used for HPLC analysis.
Blank reactions did not contain NADPH. HPLC analysis was performed
using mobile phase consisting of 40 mM potassium phosphate (pH 7.4),
acetonitrile, and tetrahydrofuran in the ratio of 89:10:1 (v/v). Formation
of metabolites was detected using a fluorescence detector set at 286 and
360 nm for excitation and emission wavelengths, respectively. Standard
morphine, codeine, and norcodeine obtained from the National Institute
of Drug Abuse was used for quantitation of metabolites. Brain variant
CYP2D7 ligated in the reverse orientation was also transfected in
Neuro2a cells and used as control.
Localization of Brain Variant P4502D7 and -Opiate Receptor in
Human Brain—Serial transverse sections (10 m thick) were cut from
a paraffin-embedded periaqueductal gray region of a human brain and
processed for immunohistochemistry as described earlier (16). Sections
were incubated with antisera to brain variant CYP2D7, -opioid recep-
tor (Sigma), or nonimmune serum and immunostaining was detected
using an ABC Elite Kit (Vector Laboratories).
RESULTS
Identification of Splice Variants of CYP2D7 from a Human
Brain cDNA Library—We investigated the presence of brain-
specific P450 by screening a human brain cortex cDNA library
using a 333-bp amplicon generated by RT-PCR of human brain
mRNA representing exons 6–9 of CYP2D6. Three positive
clones were selected, and DNA sequencing identified them as
splice variants of CYP2D7 having exon 3 deletion, partial in-
clusion of intron 6, or both (Fig. 1). Exon 3 deletion results in a
premature stop codon (TGA) at 606 bp relative to the ATG start
codon, and therefore the clones having exon 3 deletion were not
investigated further. The third clone, 1776 bp long (GenBank
accession number AY220845) with an open reading frame of
1551 bp, had an additional 57 bp from intron 6 and an intact
exon 3 of the CYP2D7 genomic sequence (GenBank accession
NG_002362). A frameshift mutation 138delT (relative to ATG)
2 The abbreviations used are: RT, reverse transcription; HPLC, high
performance liquid chromatography.
FIG. 1. Structure of splice variants of CYP2D7 gene identified
in human brain. A schematic representation of the normal spliced
CYP2D7 and the alternatively spliced forms of CYP2D7 isolated from
human brain is shown. Clone 1 contains an exon 3 deletion, clone 2 has
an exon 3 deletion and 57-bp intron 6 inclusion, and clone 3 (brain
variant CYP2D7) contains an inclusion of 57 bp of intron 6.
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modifies the stop codon TGA to GAG enabling the complete
translation of the pseudogene CYP2D7.
Expression and Functional Activity of Brain Variant
CYP2D7—The clone, which we named brain variant CYP2D7,
translated in vitro in a rabbit reticulocyte system into a 58-kDa
protein, which was immunochemically similar to hepatic
P4502D6 (Fig. 2A). The brain variant CYP2D7 was transfected
in Neuro2a cells, and the expressed protein was assessed for
P450 activity. The reduced carbon monoxide difference spec-
trum of the expressed protein had an absorption maximum at
450 nm characteristic of P450 (Fig. 2B; specific content  1.03
nmol of P450/mg of protein). The expressed protein could also
be detected by immunoblotting (Fig. 2C) and localized by im-
munohistochemistry using antibody to P4502D6 (Fig. 2D).
Neuro2a cells, per se, and those transfected with the cDNA in
the reverse orientation did not have any detectable P450 as
observed by immunohistochemistry (Fig. 2D) or by the reduced
carbon monoxide difference spectrum (data not shown).
RT-PCR and Immunoblotting Show the Presence of Brain
Variant CYP2D7 in a Subset of Individuals—A 340-bp frag-
ment representing a partial sequence of exons 6–7 including
the additional sequence of 57 bp of intron 6 representing 843–
1182 bp of brain variant CYP2D7 was amplified using RT-PCR
in 12 samples of human brain cortex obtained at autopsy. The
generation of the 340-bp amplicon indicated the expression of
the brain variant CYP2D7. Expression of CYP2D6 represented
by the 282-bp amplicon was seen in all 12 human brain sam-
ples examined (see Fig. 3A). The primers used for RT-PCR
amplified both CYP2D6 and CYP2D7 because of the consider-
able similarity (98%) between CYP2D6 and CYP2D7 in the
exon 6 region. However, the 57-bp sequence of intron 6 present
in brain variant CYP2D7 shares only 77% similarity with the
corresponding region in CYP2D6. Thus, the 340-bp RT-PCR
product represents the brain variant CYP2D7 exclusively and
was seen in 6 of the 12 samples examined.
We generated an antiserum to the 19-amino acid peptide
representing 57 bp of intron 6 present in the brain variant
CYP2D7. The peptide used to generate the antiserum did not
share homology with any known P450 enzyme, and the anti-
serum did not cross-react with P4502D6. Expression of brain
variant CYP2D7 protein as assessed by immunoblotting was
seen in 6 of the 12 brain samples (see Fig. 3B) that were
positive for the presence of brain variant CYP2D7 mRNA by
RT-PCR (Fig. 3A), indicating the concordance between the RT-
PCR and immunoblot results.
Localization of Brain Variant CYP2D7 by in Situ Hybridiza-
tion—The 340-bp RT-PCR amplicon generated as described
above was ligated into the pCRII vector for riboprobe synthesis
to localize the brain variant CYP2D7 in human tissues using in
situ hybridization. Brain variant CYP2D7 mRNA was detected
in cortical neurons in human brain but not in the liver or
kidney of the same individual (Fig. 4, A, B, and C, respectively).
However, CYP2D6 mRNA was detected in brain, liver, and
kidney when in situ hybridization was performed using the
cDNA to CYP2D6 (Fig. 4, D, E, and F, respectively).
T-Deletion in the Pseudogene CYP2D7 Generates a Func-
tional Transcript—Because the brain variant CYP2D7 is pres-
ent only in about 50% of the human brains examined, we
developed a genotyping assay to detect the 138delT relative to
ATG. The genomic DNA isolated from the 12 human brain
samples used for RT-PCR and immunoblot experiments was
used as the template. The region spanning 45–551 bp (506 bp)
relative to the ATG start codon of the genomic sequence of
CYP2D7 was amplified using PCR. The 138delT (CCTGC) was
found only in those samples in which the mRNA and protein of
the brain variant CYP2D7 were detected (Fig. 3C); others had
complete sequence similarity with the pseudogene CYP2D7
(CCTTGC).
Brain Variant CYP2D7 Metabolizes Codeine Predominantly
to Morphine—Monooxygenase activity of brain variant
CYP2D7 was ascertained by examining the metabolism of co-
deine to norcodeine and morphine. Membrane preparations
containing both mitochondria and microsomes were prepared
from Neuro2a cells transfected with the cDNA of brain variant
CYP2D7 because P450-mediated xenobiotic metabolism takes
place in both microsomes and mitochondria in rat and human
brain (13, 21). The expressed brain variant CYP2D7 metabo-
FIG. 2. Expression of brain variant CYP2D7 and assay of P450
level. A, brain variant CYP2D7 cDNA was expressed in a rabbit re-
ticulocyte system. Lane 1 contained a positive luciferase control stained
with anti-luciferase antibody. Lane 2 was loaded with an expression
system containing the vector alone, and lanes 3 and 4 contained an
expression system containing cDNA to brain variant CYP2D7. The blot
was immunostained with antibody to CYP2D6. Arrows indicate the
molecular mass of the immunostained protein. B, dithionite-reduced
carbon monoxide binding spectrum of membrane preparations from
Neuro2a cells expressing brain variant CYP2D7 protein. An absorption
maximum at 450 nm is characteristic of cytochrome P450 proteins. The
specific content of cytochrome P450 was 1.03 nmol of P450/mg of pro-
tein. C, expression of brain variant CYP2D7 protein in Neuro2a cells.
Lanes 1, 3, and 5, which contain mitochondria and microsomes from
cells transfected with vector containing the cDNA to brain variant
CYP2D7 in reverse orientation, do not show any immunostaining. Im-
munostained bands were seen in lanes 2, 4, and 6 containing mitochon-
dria and microsomes from different batches of Neuro2a cells expressing
the brain variant CYP2D7 protein. Blots were immunostained with
antibody to CYP2D6. All lanes contained 50 g of protein. D, immuno-
histochemical localization of CYP2D7 in Neuro2a cells expressing brain
variant CYP2D7. Cells expressing brain variant CYP2D7 showed in-
tense cytosolic staining (a). Cells transfected with expression vector
containing cDNA to brain variant CYP2D7 in the reverse direction
showed no staining (c). Corresponding nuclear staining with DAPI is
depicted in the right panel (b and d), respectively. Bars  50 m.
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lized 10 M codeine to morphine alone, and norcodeine could
not be detected (Fig. 5). In membranes from cells transfected
with cDNA of liver CYP2D6, norcodeine was the major metab-
olite (62%) and morphine, the minor metabolite (38%; Fig. 5B).
No metabolite of codeine was detected in cells transfected with
vector alone or vector containing the cDNA in reverse orienta-
tion (data not shown). Typically, codeine is administered at
doses ranging from 60 to 120 mg/day. The plasma concentra-
tion of codeine in humans after a single dose of 120 mg is about
474 g/liter (1.1 M); we therefore used 10 M codeine as
substrate concentration (22). When the codeine concentration
was increased to 200 M, a small amount of norcodeine (11% of
total metabolite) was formed. The Vmax/Km values for the me-
tabolism of codeine to morphine and norcodeine by brain vari-
ant CYP2D7 were 13.5 and 0.6 nmol of product formed/min/
nmol P450/mM substrate concentration, respectively. The
corresponding values with CYP2D6 were 0.8 and 1.5 nmol of
product formed/min/nmol of P450/mM substrate concentration,
respectively. Metabolism of codeine to morphine could be in-
hibited by antiserum to P4502D6 and quinidine, a selective
inhibitor of CYP2D (Fig. 5C), indicating that this biotransfor-
mation was indeed mediated by a P4502D enzyme.
Brain Variant CYP2D7 and -Opioid Receptor Colocalize in
Neurons—To determine whether the metabolism of codeine to
morphine takes place at the site of action of the morphine,
namely the neurons in periaqueductal gray that contain -opi-
ate receptors, we performed immunohistochemistry using an-
tisera to brain variant CYP2D7 and -opiate receptor on serial
sections of periaqueductal gray from human brain. Brain var-
iant CYP2D7 and -opiate receptor colocalized in the neurons
of periaqueductal gray (Fig. 6, A–D).
Incidence of CYP2D7 Genetic Polymorphism—DNA isolated
from blood samples of eight volunteers was used as a template,
and the region spanning 45–551 bp (506 bp) relative to the ATG
start codon of the genomic sequence of CYP2D7 was amplified
using PCR. The 138delT (CCTGC) was found only in 4 of 8
samples analyzed. The others had complete sequence similar-
ity with the pseudogene CYP2D7 (CCTTGC). The representa-
tive electropherogram of 6 samples is depicted in Fig. 7. Thus,
the functional CYP2D7 is presumably present in 50% of the
samples analyzed.
DISCUSSION
Several P450 enzymes, such as CYP2D (16), CYP3A (19), and
CYP2B (11), are present in human brain and localize predom-
inantly in neurons, the site of action of most drugs (19). How-
ever, drug metabolism in human brain is poorly understood,
and human brain-specific P450 enzymes remain to be identi-
fied. The presence of unique, tissue-specific P450 enzymes gen-
erated through alternate splicing provides a mechanism by
which active metabolites can be potentially formed at the site of
action of drugs within the target organ, such as the brain.
P4502D6 is an important human P450 enzyme that metab-
olizes a number of substrates (23). It shows a high degree of
interindividual variability, which is primarily caused by the
extensive genetic polymorphism that influences its expression
and function. P4502D6 is a constitutive form of hepatic P450,
FIG. 4. Localization of brain variant CYP2D7 and CYP2D6 in
human tissue. The brain variant CYP2D7 transcript was localized in
cortical neurons in human brain, but it was absent in liver and kidney
sections from the same individual (A, B, and C, respectively). The
transcript representing the full-length CYP2D6 gene was detectable in
brain, liver, and kidney (D, E, and F, respectively). Insets depict the
corresponding control sections hybridized with the sense riboprobes.
Bar  50 m except in the inset, where it  100 m.
FIG. 3. Expression of brain variant CYP2D7 and CYP2D6 in
human brain. A, RT-PCR analysis of brain variant CYP2D7 in 12
human brain autopsy samples (lanes 1–12). Brain variant CYP2D7
could be detected in 6 samples wherein a band of 340 bp was detected.
The PCR-amplified product of 280 bp representing CYP2D6 was de-
tected in all the 12 samples. M represents the DNA molecular mass
markers. B, membrane preparations from the 12 human autopsy brain
samples (lanes 1–12) were immunoblotted and stained with antiserum
to brain variant CYP2D7. Brain variant CYP2D7 protein could be
detected only in 6 brain samples, which also showed the expression of
the transcript by RT-PCR. M represents protein molecular mass mark-
ers. C, electropherogram of PCR-amplified genomic DNA from 4 brain
samples (represented in lanes 1–4 in A and B). In brain variants 1 and
2 CYP2D7 is not expressed, and the genomic sequence revealed the
presence of the pseudogene CYP2D7, as represented by the sequence
CCTTGC. In brain variants 3 and 4 CYP2D7 is expressed, and the
genomic sequence CCTGC was seen.
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where it mediates metabolism of several commonly used psy-
choactive drugs, such as imipramine, amitriptyline, chlorimi-
pramine (24), and haloperidol (25). The human CYP2D locus on
chromosome 22 consists of the three homologous genes,
CYP2D8, CYP2D7, and CYP2D6, which are located within a
contiguous region of about 45 kb (26). CYP2D8 and CYP2D7
are pseudogenes. CYP2D8 has multiple deletions and inser-
tions and no open reading frame, whereas the CYP2D7 gene
has a single inactivating mutation, an insertion (T138) in the
first exon causing a frameshift resulting in premature termi-
nation of translation of CYP2D7 (27). It has been speculated
that CYP2D7 may be expressed as a functional protein as
result of repair; however, no evidence has been presented so far
(27). Here we present evidence for the 138delT mutation that
converts the CYP2D7 pseudogene to a functional gene in about
half the samples analyzed in the present study. The mutation
138delT was seen in DNA isolated from brain tissue as well as
blood (Fig. 7), indicating that the presence of functional
CYP2D7 in these individuals. It is to be determined whether
the functional CYP2D7 is indeed present in the liver of indi-
viduals with the 138delT mutation of the CYP2D7 gene.
In individuals having the 138delT mutation, brain-specific
splicing led to the formation of a functional CYP2D7 brain
variant enzyme. Thus, in 6 of the 12 brains examined from the
Indian population genotyping revealed the presence of the
138delT mutation, and RT-PCR and immunoblot experiments
showed the presence of the brain variant CYP2D7 mRNA and
protein in these samples (Fig. 3). It is to be seen whether this
mutation exists in other population leading to the presence of
functional CYP2D7 and if it does, it is to be determined
whether the autopsy brain samples from these population ex-
FIG. 5. Metabolism of codeine by heterologously expressed
brain variant CYP2D7 and CYP2D6. A, chromatogram depicting
retention times of standard norcodeine and morphine (top panel).
CYP2D6 metabolizes codeine to norcodeine and morphine (middle
panel), whereas brain variant CYP2D7 metabolized codeine only to
morphine (bottom panel). The codeine concentration was 10 M. B, the
rate of formation of morphine and norcodeine from codeine (10 M) by
mitochondria and microsomes from cells expressing CYP2D7 brain
variant and CYP2D6. C, effect of 50 M quinidine (QUIN, an inhibitor
of P4502D) and antiserum to P4502D6 on metabolism of codeine by
Neuro2a cells transfected with CYP2D6 and brain variant CYP2D7.
The Km and Vmax for the formation of norcodeine and morphine by
CYP2D6 were 1.1 and 0.5 mM and and 1.6 and 0.4 nmol of product
formed/min/nmol of P450, respectively. The Km and Vmax for the forma-
tion of norcodeine and morphine by brain variant CYP2D7 were 1.2 and
0.1 mM and and 0.7 and 1.4 nmol of product formed/min/nmol of P450,
respectively. The S.E. was less than 5%.
FIG. 6. Localization of brain variant CYP2D7 and -opioid re-
ceptors in periaqueductal gray of human brain. A and B, antiserum
to brain variant CYP2D7 labels neurons in periaqueductal gray of human
brain. Bar  25 and 10 m, respectively. C, control section treated with
nonimmune rabbit serum. Bar  10 m. D and E, serial section shows
staining in the same neurons as in A and B when treated with antiserum
to -opioid receptor. Bar 25 and 10 m, respectively. F, control sections
immunostained with normal rabbit serum. Bar  10 m.
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press the brain variant CYP2D7 that is generated by brain-
specific alternate splicing.
The brain variant CYP2D7 has a partial inclusion of intron 6
(57 bp) in the transcribed mRNA sequence. This was observed
only in human brain and not in liver or kidney of the same
individual, indicating that generation of alternate spliced form
is a brain-specific event. Earlier studies have shown the pres-
ence of an alternate spliced form of flavin-containing monooxy-
genase (FMO4) with an exon 4 deletion in rat brain but not in
other tissues (28). The nervous system has a propensity for
generating alternate spliced forms, and splicing defects ob-
served in individuals are not related to differences in the
genomic sequence but may be regulated by mechanisms involv-
ing spliceosomal complex and RNA-binding proteins, which are
poorly understood (29).
The tendency for human brain to generate alternate spliced
genes is seen in the present study wherein three alternate
spliced variants were identified in the human brain, namely,
exon 3 deletion, partial inclusion of intron 6, and a third having
both the deletion and inclusion. The alternate spliced variants
containing exon 3 deletion have a premature stop codon, which
prevents their translation into functional gene products. Thus,
estimation of P450 isoforms by examining gene expression
using Northern blotting, RT-PCR, and in situ hybridization
(16, 30, 31) would represent contributions from functional and
nonfunctional genes and would potentially overestimate the
expression of a particular isoform. The well characterized
CYP2D6 exhibits genetic polymorphism, and the gene is absent
in the “poor metabolizer (PM)” phenotype (32). None of the
individuals whose brain samples were studied lacked the
CYP2D6 gene as discerned by the presence of the 282-bp am-
plicon, whereas the brain variant CYP2D7 form was expressed
in 6 but not in others.
Plasma levels of morphine show poor correlation with pain
relief provided by codeine (33) because the amount of morphine
formed in liver through P4502D6 metabolism of codeine is
insufficient to account for the analgesic effect of codeine (34). It
has been speculated that human brain-specific metabolic path-
ways, which can metabolize codeine to morphine, exist which
are yet to be identified (35, 36). Thus, even if a very small
amount of codeine is metabolized to morphine by brain P450 at
the site of action, it could mediate pain relief (37). The results
presented herein provide evidence for the formation of mor-
phine from codeine by brain-specific alternate spliced gene
product leading to a metabolite(s) profile that is different from
liver.
In cells transfected with CYP2D6, norcodeine was the major
metabolite and morphine, the minor metabolite. Earlier stud-
ies had indicated that the metabolism of codeine to norcodeine
is mediated by P4503A4 (38); however, in the present study it
is seen that P4502D6 also metabolizes codeine principally to
norcodeine. However, brain variant CYP2D7 metabolizes co-
deine largely to morphine, and norcodeine is formed in lesser
amounts and only at higher substrate concentration. Morphine
is exclusively formed at a lower concentration of codeine (10
M) which is closer the physiological concentration achieved
after administration of a pharmacological dose of codeine (22).
For effective pain relief it would be ideal if morphine were
formed in the brain where it can directly bind to -opioid
receptors. Opiates mediate their central analgesic effects by
acting on neurons within brain regions such as the midbrain
periaqueductal gray (39). We localized brain variant P4502D7
and -opiate receptor by immunohistochemistry in the periaq-
ueductal gray region of a human brain obtained at autopsy.
The brain variant CYP2D7 and -opiate receptor are colocal-
ized in the neurons of periaqueductal gray, indicating that
morphine could potentially be formed from codeine in pain
centers of the central nervous system. Biochemical estimation
of enzyme activity represents the average in a tissue containing
several distinct cell types. In heterogeneous tissues, such as the
brain, low levels of enzyme activity may be observed. However,
because enzymes such as P450 are localized in selective cell
population (Figs. 2D and 6), which are the site of action of
drugs, it is not the total specific content of the enzyme that
would determine the outcome, but the site specificity and the
amount of enzyme present in individual cell types. The total
P450 levels in human brain are typically only 4–10% of the
corresponding levels in the liver (40); however, the presence of
brain-specific isoforms of P450 in specific cell population indi-
cates that they may play an important role in metabolism of
drugs, in situ, at the site of action. Although genetic polymor-
phism of CYP2D6 is one of the important determinants of
interindividual variation in drug response, functional polymor-
phism of CYP2D6 does not always correlate with therapeutic
efficacy (8). We now present evidence for the existence of a
pathway that can potentially mediate pharmacological action
FIG. 7. Electropherogram of PCR-
amplified genomic DNA from blood
samples of six individuals. Electro-
pherogram of PCR-amplified genomic
DNA from six blood samples is repre-
sented in A and B. A, the genomic se-
quence CAACCTGCTGCA was seen, indi-
cating the presence of functional
CYP2D7. B, the genomic sequence CAAC-
CTTGCTGCA indicates the presence of
the pseudogene CYP2D7.
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of codeine at the site of action by mechanisms that are dissim-
ilar from known pathways in liver. Identification and charac-
terization of novel histio-specific isoforms of P450 generated by
alternate splicing of known genes or as yet unidentified genes
may help predict the pharmacological outcome of drugs that act
at sites remote from liver.
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